Is hepatitis C virus genotyping required before prescribing Mavyret (glecaprevir/pibrentasvir)?

Genotyping is NOT Required to Prescribe Mavyret

No, you do not have to perform HCV genotyping before prescribing Mavyret (glecaprevir/pibrentasvir). Mavyret is a pangenotypic regimen approved for all HCV genotypes 1-6, and current guidelines explicitly support simplified, genotype-free treatment approaches 1.

Guideline-Based Approach

Simplified Treatment Strategy

The EASL 2020 guidelines provide clear recommendations for genotype-free treatment 1:

• Treatment-naïve patients without cirrhosis: 8 weeks of glecaprevir/pibrentasvir
• Treatment-naïve patients with compensated cirrhosis (Child-Pugh A): 8 weeks of glecaprevir/pibrentasvir
• Treatment-experienced patients without cirrhosis: 8 weeks of glecaprevir/pibrentasvir
• Treatment-experienced patients with compensated cirrhosis: 12 weeks of glecaprevir/pibrentasvir

These recommendations explicitly state that treatment can proceed "without testing genotype/subtype" when using pangenotypic regimens like Mavyret 1.

FDA Label Confirmation

The FDA-approved prescribing information for Mavyret confirms its indication for "chronic HCV genotype 1,2,3,4,5 or 6 infection" without requiring genotyping as a prerequisite for treatment 2. The label provides treatment duration based on cirrhosis status and treatment history, not genotype.

When Genotyping May Still Be Useful

While not required, genotyping remains "useful to optimize the virological results" in certain situations 1:

Specific Clinical Scenarios Where Genotyping Adds Value:

1. Genotype 3 with compensated cirrhosis: Identifying GT3 allows for optimized treatment duration (12-16 weeks vs. 8 weeks) and consideration of alternative regimens with ribavirin if treatment-experienced 1

2. Treatment-experienced patients: Knowing the genotype helps determine optimal duration (8 vs. 12 vs. 16 weeks) 3, 1

3. Rare subtypes in high-risk populations: Patients from sub-Saharan Africa, China, or Southeast Asia may harbor infrequent subtypes (1l, 4r, 3b, 3g, 6u, 6v) with baseline NS5A resistance that could benefit from alternative regimens 1

4. Cost considerations: Identifying genotype 1b allows use of less expensive non-pangenotypic options like grazoprevir/elbasvir in resource-limited settings 1

Practical Algorithm for Prescribing Mavyret Without Genotyping

Step 1: Confirm HCV RNA positive (active infection)

Step 2: Assess cirrhosis status (imaging, FibroScan, or labs)

• No cirrhosis or compensated (Child-Pugh A) → Proceed
• Decompensated (Child-Pugh B/C) → Contraindicated 2

Step 3: Determine treatment history

• Treatment-naïve → 8 weeks
• Treatment-experienced (PEG-IFN/RBV/sofosbuvir only) → 8 weeks (no cirrhosis) or 12 weeks (cirrhosis)
• NS5A or NS3/4A inhibitor-experienced → Consider genotyping for optimal duration

Step 4: Check for contraindications

• Atazanavir or rifampin use → Contraindicated 2
• Moderate/severe hepatic impairment → Contraindicated 2

Step 5: Test for HBV coinfection (HBsAg, anti-HBc) - This is mandatory 2

Common Pitfalls to Avoid

1. Don't delay treatment waiting for genotype results: The simplified approach allows immediate treatment initiation, which is critical for patient retention, especially in high-risk populations like people who inject drugs 4, 5

2. Don't assume genotyping is needed for insurance approval: Most payers now accept pangenotypic regimens without genotype documentation

3. Don't forget HBV testing: While HCV genotyping is optional, HBV testing is mandatory before starting any DAA therapy due to reactivation risk 2

4. Don't use Mavyret in decompensated cirrhosis: This is an absolute contraindication regardless of genotype 2

Real-World Evidence

Multiple real-world studies confirm excellent outcomes with genotype-free Mavyret treatment, with SVR12 rates of 96-100% across all genotypes 6, 7, 8, 9. The AASLD/IDSA 2020 guidelines note that Mavyret's "pangenotypic activity" allows it to be "the first choice for adolescent HCV treatment" without requiring genotype determination 3.

Bottom line: Prescribe Mavyret based on cirrhosis status and treatment history alone. Reserve genotyping for situations where it changes management (GT3 with cirrhosis, treatment-experienced patients, or cost-driven regimen selection).